vs
Journey Medical Corp（DERM）与NexPoint Real Estate Finance, Inc.（NREF）财务数据对比。点击上方公司名可切换其他公司
Journey Medical Corp的季度营收约是NexPoint Real Estate Finance, Inc.的1.4倍（$16.1M vs $11.1M），NexPoint Real Estate Finance, Inc.净利率更高（216.6% vs -7.8%，领先224.4%），Journey Medical Corp同比增速更快（27.3% vs -48.8%）
Journey Medical Corp是一家处于商业化阶段的生物制药企业，专注于皮肤病治疗领域，研发、生产并销售处方及非处方皮肤用药，覆盖痤疮、特应性皮炎、皮肤真菌感染等适应症，主要服务美国市场的医疗机构与患者。
NexPoint Real Estate Finance, Inc.是一家总部位于美国的商业地产金融企业，主要为多户住宅、写字楼、工业及酒店物业提供结构化融资方案，运营并管理抵押贷款及其他地产相关投资组合，为利益相关方提供经风险调整的稳定回报。
DERM vs NREF — 直观对比
营收规模更大
DERM
是对方的1.4倍
$11.1M
营收增速更快
DERM
高出76.1%
-48.8%
净利率更高
NREF
高出224.4%
-7.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.1M | $11.1M |
| 净利润 | $-1.2M | $24.0M |
| 毛利率 | — | — |
| 营业利润率 | -2.8% | — |
| 净利率 | -7.8% | 216.6% |
| 营收同比 | 27.3% | -48.8% |
| 净利润同比 | -182.0% | 58.7% |
| 每股收益（稀释后） | $-0.04 | $0.47 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DERMNREF
| Q4 25 | $16.1M | $11.1M | ||
| Q3 25 | $17.0M | $12.5M | ||
| Q2 25 | $15.0M | $12.1M | ||
| Q1 25 | $13.1M | $11.5M | ||
| Q4 24 | $12.6M | $21.7M | ||
| Q3 24 | $14.6M | $12.5M | ||
| Q2 24 | $14.9M | $6.7M | ||
| Q1 24 | $13.0M | $-12.8M |
净利润DERMNREF
| Q4 25 | $-1.2M | $24.0M | ||
| Q3 25 | $-2.3M | $50.9M | ||
| Q2 25 | $-3.8M | $22.3M | ||
| Q1 25 | $-4.1M | $26.0M | ||
| Q4 24 | $1.5M | $15.2M | ||
| Q3 24 | $-2.4M | $23.3M | ||
| Q2 24 | $-3.4M | $12.1M | ||
| Q1 24 | $-10.4M | $-14.6M |
毛利率DERMNREF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
营业利润率DERMNREF
| Q4 25 | -2.8% | — | ||
| Q3 25 | -9.0% | — | ||
| Q2 25 | -19.2% | — | ||
| Q1 25 | -25.3% | — | ||
| Q4 24 | 17.7% | — | ||
| Q3 24 | -19.8% | — | ||
| Q2 24 | -19.7% | — | ||
| Q1 24 | -77.4% | — |
净利率DERMNREF
| Q4 25 | -7.8% | 216.6% | ||
| Q3 25 | -13.6% | 407.0% | ||
| Q2 25 | -25.3% | 184.5% | ||
| Q1 25 | -31.0% | 225.6% | ||
| Q4 24 | 12.1% | 69.9% | ||
| Q3 24 | -16.3% | 186.4% | ||
| Q2 24 | -22.6% | 179.7% | ||
| Q1 24 | -80.1% | 114.3% |
每股收益（稀释后）DERMNREF
| Q4 25 | $-0.04 | $0.47 | ||
| Q3 25 | $-0.09 | $1.14 | ||
| Q2 25 | $-0.16 | $0.54 | ||
| Q1 25 | $-0.18 | $0.70 | ||
| Q4 24 | $0.10 | $0.71 | ||
| Q3 24 | $-0.12 | $0.74 | ||
| Q2 24 | $-0.17 | $0.40 | ||
| Q1 24 | $-0.53 | $-0.83 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $24.1M | $31.1M |
| 总债务越低越好 | $25.3M | $771.2M |
| 股东权益账面价值 | $31.9M | $388.0M |
| 总资产 | $94.6M | $5.3B |
| 负债/权益比越低杠杆越低 | 0.79× | 1.99× |
8季度趋势，按日历期对齐
现金及短期投资DERMNREF
| Q4 25 | $24.1M | $31.1M | ||
| Q3 25 | $24.9M | $17.9M | ||
| Q2 25 | $20.3M | $9.1M | ||
| Q1 25 | $21.1M | $19.2M | ||
| Q4 24 | $20.3M | $3.9M | ||
| Q3 24 | $22.5M | $34.7M | ||
| Q2 24 | $23.9M | $4.3M | ||
| Q1 24 | $24.1M | $13.5M |
总债务DERMNREF
| Q4 25 | $25.3M | $771.2M | ||
| Q3 25 | $25.2M | $720.9M | ||
| Q2 25 | $25.1M | $815.6M | ||
| Q1 25 | $25.0M | $831.5M | ||
| Q4 24 | $24.9M | $799.3M | ||
| Q3 24 | $19.8M | $815.5M | ||
| Q2 24 | $19.7M | $861.0M | ||
| Q1 24 | $14.7M | $843.3M |
股东权益DERMNREF
| Q4 25 | $31.9M | $388.0M | ||
| Q3 25 | $25.9M | $375.4M | ||
| Q2 25 | $19.2M | $348.2M | ||
| Q1 25 | $21.5M | $343.7M | ||
| Q4 24 | $20.1M | $336.5M | ||
| Q3 24 | $10.9M | $335.8M | ||
| Q2 24 | $11.3M | $327.5M | ||
| Q1 24 | $13.0M | $327.1M |
总资产DERMNREF
| Q4 25 | $94.6M | $5.3B | ||
| Q3 25 | $85.2M | $5.3B | ||
| Q2 25 | $81.2M | $5.4B | ||
| Q1 25 | $85.0M | $5.4B | ||
| Q4 24 | $80.2M | $5.4B | ||
| Q3 24 | $64.0M | $5.7B | ||
| Q2 24 | $65.2M | $6.6B | ||
| Q1 24 | $66.6M | $7.1B |
负债/权益比DERMNREF
| Q4 25 | 0.79× | 1.99× | ||
| Q3 25 | 0.97× | 1.92× | ||
| Q2 25 | 1.30× | 2.34× | ||
| Q1 25 | 1.16× | 2.42× | ||
| Q4 24 | 1.24× | 2.38× | ||
| Q3 24 | 1.81× | 2.43× | ||
| Q2 24 | 1.75× | 2.63× | ||
| Q1 24 | 1.13× | 2.58× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.3M | $-4.5M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | -0.19× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DERMNREF
| Q4 25 | $-6.3M | $-4.5M | ||
| Q3 25 | $-2.4M | $8.1M | ||
| Q2 25 | $-942.0K | $3.3M | ||
| Q1 25 | $-2.8M | $16.0M | ||
| Q4 24 | $2.2M | $4.4M | ||
| Q3 24 | $-1.2M | $14.7M | ||
| Q2 24 | $-5.2M | $-7.5M | ||
| Q1 24 | $-5.0M | $17.7M |
现金转化率DERMNREF
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.62× | ||
| Q4 24 | 1.46× | 0.29× | ||
| Q3 24 | — | 0.63× | ||
| Q2 24 | — | -0.62× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
NREF
暂无分部数据
